Cargando…
Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients
Tumor-associated lymphocytes (TALs) have been successfully isolated from ascites and solid tumors, however the clinical use of TALs in treating ovarian cancer (OC) has not yet been reported. The present study investigated the efficacy and toxicity of TALs in the presence or absence of chemotherapy i...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587970/ https://www.ncbi.nlm.nih.gov/pubmed/28927091 http://dx.doi.org/10.3892/ol.2017.6635 |
_version_ | 1783262095043723264 |
---|---|
author | Zhang, Weiwei Liu, Kejun Ye, Bin Hu, Guolin Zhao, Kelei Ren, Yazhou Liang, Weijiang |
author_facet | Zhang, Weiwei Liu, Kejun Ye, Bin Hu, Guolin Zhao, Kelei Ren, Yazhou Liang, Weijiang |
author_sort | Zhang, Weiwei |
collection | PubMed |
description | Tumor-associated lymphocytes (TALs) have been successfully isolated from ascites and solid tumors, however the clinical use of TALs in treating ovarian cancer (OC) has not yet been reported. The present study investigated the efficacy and toxicity of TALs in the presence or absence of chemotherapy in OC patients with malignant ascites (MA). A total of 32 patients were enrolled in this study. A total of 8 patients received treatment with TALs alone (TALs group), 11 patients received combined treatment of TALs and chemotherapy (combination group) and 13 patients received chemotherapy alone (chemotherapy group). The endpoints included Karnofsky performance status (KPS), ascites-associated symptoms (AAS), time to progression (TTP) and overall survival (OS). Compared with the TALs and chemotherapy group, the KPS and AAS in the combination group significantly improved following treatment. Patients in the TALs group (37.5%) and chemotherapy group (53.8%) achieved significantly fewer objective response rates of ascites compared with those in the combination group (90.9%). Furthermore, combination therapy significantly extended TTP (13 months) compared with TALs alone (1 month, P<0.001), and chemotherapy alone (6 months, P=0.027). Similar results were observed for OS between the combination group and the TALs group (25 vs. 7 months, P<0.001). The present study therefore demonstrates that combined therapy of TALs and chemotherapy is safe, feasible, and more effective than chemotherapy or TALs alone in controlling MA and improving the quality of life for OC patients. |
format | Online Article Text |
id | pubmed-5587970 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-55879702017-09-18 Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients Zhang, Weiwei Liu, Kejun Ye, Bin Hu, Guolin Zhao, Kelei Ren, Yazhou Liang, Weijiang Oncol Lett Articles Tumor-associated lymphocytes (TALs) have been successfully isolated from ascites and solid tumors, however the clinical use of TALs in treating ovarian cancer (OC) has not yet been reported. The present study investigated the efficacy and toxicity of TALs in the presence or absence of chemotherapy in OC patients with malignant ascites (MA). A total of 32 patients were enrolled in this study. A total of 8 patients received treatment with TALs alone (TALs group), 11 patients received combined treatment of TALs and chemotherapy (combination group) and 13 patients received chemotherapy alone (chemotherapy group). The endpoints included Karnofsky performance status (KPS), ascites-associated symptoms (AAS), time to progression (TTP) and overall survival (OS). Compared with the TALs and chemotherapy group, the KPS and AAS in the combination group significantly improved following treatment. Patients in the TALs group (37.5%) and chemotherapy group (53.8%) achieved significantly fewer objective response rates of ascites compared with those in the combination group (90.9%). Furthermore, combination therapy significantly extended TTP (13 months) compared with TALs alone (1 month, P<0.001), and chemotherapy alone (6 months, P=0.027). Similar results were observed for OS between the combination group and the TALs group (25 vs. 7 months, P<0.001). The present study therefore demonstrates that combined therapy of TALs and chemotherapy is safe, feasible, and more effective than chemotherapy or TALs alone in controlling MA and improving the quality of life for OC patients. D.A. Spandidos 2017-09 2017-07-20 /pmc/articles/PMC5587970/ /pubmed/28927091 http://dx.doi.org/10.3892/ol.2017.6635 Text en Copyright: © Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Zhang, Weiwei Liu, Kejun Ye, Bin Hu, Guolin Zhao, Kelei Ren, Yazhou Liang, Weijiang Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients |
title | Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients |
title_full | Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients |
title_fullStr | Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients |
title_full_unstemmed | Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients |
title_short | Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients |
title_sort | clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587970/ https://www.ncbi.nlm.nih.gov/pubmed/28927091 http://dx.doi.org/10.3892/ol.2017.6635 |
work_keys_str_mv | AT zhangweiwei clinicalandbiologicaleffectsoftumorassociatedlymphocytesinthepresenceorabsenceofchemotherapyformalignantascitesinovariancancerpatients AT liukejun clinicalandbiologicaleffectsoftumorassociatedlymphocytesinthepresenceorabsenceofchemotherapyformalignantascitesinovariancancerpatients AT yebin clinicalandbiologicaleffectsoftumorassociatedlymphocytesinthepresenceorabsenceofchemotherapyformalignantascitesinovariancancerpatients AT huguolin clinicalandbiologicaleffectsoftumorassociatedlymphocytesinthepresenceorabsenceofchemotherapyformalignantascitesinovariancancerpatients AT zhaokelei clinicalandbiologicaleffectsoftumorassociatedlymphocytesinthepresenceorabsenceofchemotherapyformalignantascitesinovariancancerpatients AT renyazhou clinicalandbiologicaleffectsoftumorassociatedlymphocytesinthepresenceorabsenceofchemotherapyformalignantascitesinovariancancerpatients AT liangweijiang clinicalandbiologicaleffectsoftumorassociatedlymphocytesinthepresenceorabsenceofchemotherapyformalignantascitesinovariancancerpatients |